Skip to content. | Skip to navigation

Personal tools
You are here: Home > Basic Research > Faculty > Thomas Mitchell, Ph.D.

Thomas Mitchell, Ph.D.

by Eaves JR,Baxter Slaten last modified Dec 20, 2013 11:59 AM

Thomas C. Mitchell, Ph.D.

Professor of Microbiology and Immunology

Barnstable-Brown Chair in Diabetes Research


Research Interests

  • Low toxicity adjuvant effects on T cells
  • Mechanisms of activated T cell survival during immune responses


Professional Bio 

2006 - present
Associate Professor of Microbiology and Immunology University of Louisville School of Medicine Institute for Cellular Therapeutics 
 2000 - 2006
Assistant Professor of Microbiology and Immunology University of Louisville School of Medicine Institute for Cellular Therapeutics
 1995 - 2000
Postdoctoral Research Fellow Howard Hughes Medical Institute National Jewish Medical and Research Center with John W. Kappler, Ph.D. and Philippa C. Marrack, Ph.D.
 1993 - 1995
Postdoctoral Research Fellow The McArdle Laboratory for Cancer Research The University of Wisconsin-Madison with Bill Sugden, Ph.D.
 1986 - 1992
Ph.D. (Cell and Molecular Biology) The University of Wisconsin-Madison with Rex Risser, Ph.D. (deceased) and Howard M. Temin, Ph.D. (deceased)
 1982 - 1986
B.S., with Honors and with High Distinction The University of Michigan



Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, and Mitchell TC. The Vaccine Adjuvant Monophosphoryl Lipid A as a Trif-biased Agonist of TLR4.  Science, 2007; 316(5831):1628-1632.
Perspective on this paper published in Science, 2007; 316(5831):1574-1576.

Sengupta S, Jayaraman P, Chilton PM, Casella CR and Mitchell TC.  Unrestrained glycogen synthase kinase-3beta activity leads to activated T cell death and can be inhibited by natural adjuvant.

The Journal of Immunology, 2007; 178(10):6083-91.
8(10):6083-91, 2007.

Chilton PM and Mitchell TC. CD8 T cells require Bcl-3 for maximal gamma interferon production upon secondary exposure to antigen.

Infection and Immunity, 2006; 74(7):4180-9.

Chilton PM, Jayaraman P, Cai M, Mitchell TC. Adjuvant-mediated effects on activated T cell survival and the divergent roles played by Bcl-3.

Research Signpost 2006, Vella A.T., editor.

Sengupta S, Chilton PM, and Mitchell TC. Adjuvant-induced survival signaling in clonally expanded T cells is associated with transient increases in pAKT levels and sustained uptake of glucose.

Immunobiology, 2005; 210(9):647-59.

Thompson BS, Chilton PM, Ward JR, Evans JT, and Mitchell TC. The low toxicity versions of LPS, MPL ® adjuvant and RC529, are efficient adjuvants for CD4 + T cells.

Journal of Leukocyte Biology, 2005; 78(6):1273-80.

Thompson BS, Mata-Haro V, Casella CR, and Mitchell TC. Peptide-stimulated DO11.10 T cells divide well but accumulate poorly in the absence of TLR agonist treatment.

European Journal of Immunology, 2005; 35(11):3196-3208.

Thompson BS and Mitchell TC. An in vivo method to determine the average survival of daughter cells following T cell activation.

J. Immunological Methods, 2004;295:79-87.

Hildeman DA, Mitchell T, Kappler J, Marrack P. T cell apoptosis and reactive oxygen species.
J. Clin. Invest., 2003; 111:575-81.

Hildeman DA, Mitchell T, Aronow B, Wojciechowski S, Kappler J, Marrack P. Control of Bcl-2 expression by reactive oxygen species.

Proc. Natl. Acad. Sci. USA , 2003;100:15035-40.

Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P. Molecular mechanisms of activated T cell death in vivo.

Curr Opin Immunol. 2002;14(3):354-9.

Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, Kappler J, Marrack P. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim.

Immunity, 2002; 16(6):759-67.

Swanson BJ, Murakami M., Mitchell TC, Kappler J, and Marrack P. RANTES production by memory phenotype T cells is controlled by a posttranscriptional, TCR dependent process.

Immunity, 2002; 17:605-615.

Mitchell TC , Thompson BS, Trent JO, and Casella CR. A short domain within Bcl-3 is responsible for its lymphocyte survival activity.

Ann. NY Acad. Sci., 2002; 975:132-147.

Mitchell TC , Teague KT, Hildeman DA, Bender J, Ress WA, Kedl RM, Swanson B, Kappler JW, and Marrack P. Stronger correlation of Bcl-3 than Bcl-2, Bcl-xL, costimulation, or antioxidants with adjuvant-induced T cell survival.

Ann. NY Acad Sci., 2002; 975:114-131.

Schaefer B.C., Mitchell T.C ., Kappler J.W., Marrack P. A novel family of retroviral vectors for the rapid production of complex stable cell lines.

Anal Biochem., 2001; 297(1):86-93.

Mitchell TC, Hildeman D, Kedl RM, Teague TK, Schaefer BC, White J, Zhu Y, Kappler J, and Marrack P. Immunological adjuvants promote activated T cell survival via induction of Bcl-3.

Nature Immunology, 2001; 2(5):1-7.

Marrack P, Mitchell T, Hildeman D, Kedl R, Teague TK, Bender J, Rees W, Schaefer BC, Kappler J. Genomic-scale analysis of gene expression in resting and activated T cells.

Curr Opin Immunol 2000;12(2):206-9.

Hildeman DA, Mitchell T, Teague TK, Henson P, Day BJ, Kappler J, Marrack PC. Reactive oxygen species regulate activation-induced T cell apoptosis.

Immunity. 1999;10(6):735-44.

Mitchell T, Kappler J, Marrack P. Bystander virus infection prolongs activated T cell survival.  

J Immunol. 1999;162(8):4527-35.

Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive.  J Exp Med.


Marrack P, Mitchell T, Bender J, Hildeman D, Kedl R, Teague K, Kappler

J. T-cell survival. Immunol Rev. 1998;165:279-85.




Document Actions
Personal tools